Clinical trials: Malaria Vaccines
Malaria Vaccine
Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years
This is a clinical trial in which healthy volunteers will receive one of three investigational malaria vaccines (LYB014, LYB017, and LYB027) administered in combination with the A02B adjuvant, or the A02B adjuvant alone as the…
- Trial name
- NCT07831226
- Testing
- LYB014 low dose, LYB014 high dose, LYB017 low dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Malaria Vaccines, Malaria (Plasmodium Falciparum)
Infant Malaria Vaccine Schedule Optimization
The aim of this study is to identify an optimal infant vaccine schedule for a malaria vaccine which is better aligned with the timing of other vaccine interventions.
- Trial name
- NCT06879327
- Testing
- R21 Matrix-M (R21/MM) Malaria Vaccine, Hexavalent Vaccine, Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- 2 sites in Burkina Faso
- Volunteers
- 975 people, healthy volunteers welcome
- Sponsor
- PATH
Plasmodium Falciparum Malaria, Malaria
R21/MM Dosing, Presentations, and Preservatives
This is a single blind randomised controlled trial (Phase 3 trial). This study aims to assess whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in children and adults.
- Conditions
- Plasmodium Falciparum Malaria, Malaria, Vaccine Reaction
- Trial name
- VAC100 (NCT07194668)
- Testing
- 10μg R21/50μg Matrix-M, 5μg R21/50μg Matrix-M with adaptor preservative free, 5μg R21/50μg Matrix-M with 2PE preservative
- Where
- 2 sites in Bangladesh
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria Infection, Malaria Vaccines
Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad
This is a two-arm, cluster-randomised, phase IV trial conducted in Chad to assess the protective efficacy and impact in real-life conditions of a new strategy for administering the R21/MM malaria vaccine, synchronized within a…
- Trial name
- COSAV-R21 (NCT07038837)
- Testing
- "Synchronised" arm (intervention)
- Where
- Chad
- Volunteers
- 70,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Plasmodium Vivax Infection, Malaria Vaccine
A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )
This project is the third part of a 5-year research program entitled "Malaria Infection Studies in Thailand (MIST)" and known as MIST3.
- Trial name
- MIST3 (NCT05380388)
- Testing
- Malaria Vaccine, HBV vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Malaria Vaccines
A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa
The RTS, S/AS01E vaccine was developed to protect children in sub-Saharan Africa from malaria as part of routine immunization programs. This study aims to check the vaccine's safety after it has been introduced.
- Trial name
- EPI-MAL-003 (NCT03855995)
- Testing
- Whole blood sample
- Where
- 6 sites in Ghana, Kenya and 1 more
- Volunteers
- 77,953 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Invasive Non-Typhoidal Salmonella Disease, Malaria
Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease
The goal of this observational study is to learn about the impact of malaria vaccination on the risk of invasive non-typhoidal Salmonella disease in children below the age of 5.
- Conditions
- Invasive Non-Typhoidal Salmonella Disease, Malaria, Malaria Vaccine
- Trial name
- VINS (NCT07416461)
- Testing
- R21/Matrix-M malaria vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 10,000 people
- Sponsor
- International Vaccine Institute
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Malaria, Malaria Vaccine, Insecticide-treated Bednets
RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi
The overall goal of this study is to assess the impact of RTS,S (malaria) vaccination and PBO nets on malaria infection and transmission, independently and how they interact when they are introduced together.
- Trial name
- RTSS/PBO (NCT04327440)
- Testing
- RTS,S/AS01 malaria vaccine, PBO bed nets
- Where
- Malawi
- Volunteers
- 1,691 people, healthy volunteers welcome
- Sponsor
- Michigan State University
Malaria, Malaria Vaccine
Knowledge and Attitude Among Healthcare Workers Towards Malaria Vaccine, Sudan 2025.
This study assesses Sudanese healthcare workers' knowledge and attitudes toward the malaria vaccine in 2025, considering demographic and professional factors.
- Trial name
- NCT07194499
- Testing
- No interventions
- Where
- Sudan
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Research and Publication office
Malaria Vaccine
Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa
This is a multi-site, multi-disciplinary, Phase-4 two-arm cluster-randomised non-inferiority trial in Burkina Faso and Mali to evaluate the effectiveness and real-life impact of a novel integrated delivery strategy of the R21…
- Trial name
- IMVACS (NCT06860178)
- Testing
- Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months
- Where
- 2 sites in Burkina Faso, Mali
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Malaria, Malaria Vaccines
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
This epidemiology study was conducted in parallel with the EPI-MAL-002 (NCT02374450) and EPI-MAL-003 (NCT03855995) studies, enrolling participants from the same health and demographic surveillance system (HDSS) (or equivalent…
- Trial name
- NCT02251704
- Testing
- Assessment of body temperature, Blood sampling
- Where
- 12 sites in Burkina Faso, Ghana and 4 more
- Volunteers
- 54,115 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccine Reaction
A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults
A Phase 1, open label clinical study to evaluate the safety, immunogenicity, tolerability and efficacy of Plasmodium falciparum Malaria Protein 013 (FMP013) combined with (ALF with QS-21), saponin molecule derived from the bark…
- Trial name
- NCT04268420
- Testing
- FMP013, ALFQ
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria Vaccine
Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults
Targeted malaria elimination (TME), which comprises appropriate case management by village health workers, vector control and mass drug administration, is currently being implemented through pilot projects in selected villages in…
- Trial name
- RTSS (NCT02992119)
- Testing
- RTS,S/AS01B Fractional dose, Double RTS,S/AS01E Fractional dose, RTS,S/AS01E Standard dose
- Where
- Thailand
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Malaria Vaccines
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of the SB257049 candidate malaria vaccine when co-administered with Vitamin A, measles, rubella and yellow fever vaccines to children aged 6…
- Trial name
- NCT02699099
- Testing
- Vitamin A, Candidate Plasmodium falciparum malaria vaccine, MR-Vac
- Where
- 2 sites in Ghana
- Volunteers
- 699 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Malaria Vaccines
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
GSK Biologicals in partnership with the Malaria Vaccine Initiative at PATH is developing a candidate malaria vaccine GSK 257049 for the routine immunization of infants and children living in malaria endemic areas.
- Trial name
- NCT00289185
- Testing
- RTS,S/AS02D, Engerix-B®, TETRActHib™
- Where
- Tanzania
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Malaria Vaccines
Epidemiology Study of Malaria Transmission Intensity in Africa
The aim of this epidemiology study is to characterize in a standardized way malaria transmission intensity at the clinical trial centers participating in study 110021 (NCT00866619).
- Trial name
- NCT01190202
- Testing
- Blood sampling, Assessment of body temperature
- Where
- 8 sites in Burkina Faso, Gabon and 4 more
- Volunteers
- 21,618 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Anemia, Iron Deficiency
Iron and Prebiotics Fortification in Kenyan Infants
Iron deficiency and anemia are health issues affecting mainly infants and women in developing countries. Iron deficiency in infancy can have long-lasting impact on cognitive and motor development of the child.
- Conditions
- Anemia, Iron Deficiency, Diarrhea, Malaria
- Trial name
- Iro'n'Pre (NCT02118402)
- Testing
- Fortified maize porridge
- Where
- Kenya
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Swiss Federal Institute of Technology
Malaria, Malaria Vaccines
Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)
This study has been designed to support the indication of the candidate vaccine (also referred to as GSK 257049 or RTS,S in this record) against hepatitis B virus infection, when administered as a primary vaccination integrated…
- Trial name
- NCT01345240
- Testing
- GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049, Engerix-B™ vaccine, Infanrix/Hib™ vaccine
- Where
- 2 sites in Burkina Faso, Ghana
- Volunteers
- 705 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccine Reaction, Anemia
Non-specific Effects of Vaccination on Mortality and Morbidity
It has long been recognized that the positive effects of vaccination on childhood mortality cannot be solely attributed to a decline in the disease targeted by the vaccine.
- Conditions
- Vaccine Reaction, Anemia, Malaria,Falciparum, Salmonella Bacteraemia
- Trial name
- NOVAC (NCT03176719)
- Testing
- Venipuncture
- Where
- Burkina Faso
- Volunteers
- 1,005 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center